Overview
Improving Outcomes and Expanding Opportunities for the Treatment of Hyperlipidemia
Enduring Program
Click the"View Activity" button to view this activity.
View ActivityCME/CE is no longer available for this activity
As presented at the 2018 C3 annual meeting, clinicians can learn about strategies to effectively apply new cholesterol therapies in diverse patient populations, clinical implications of the latest outcomes data from the FOURIER, ODYSSEY and SPIRE Trials, and access, cost, and non-adherence challenges of PCSK9 inhibitor therapy.
This educational activity is designed for clinicians involved in the management and treatment of patients with hyperlipidemia.
Significant changes were introduced in the 2013 guidelines on the treatment of blood cholesterol, including less reliance on LDL-C and HDL-C targets. Treatment decisions for hyperlipidemia are increasingly challenging as clinicians must determine which patients are at high-risk and require intensification or switching to a new therapy. Data from the cardiovascular outcomes trials with the PCSK9 inhibitors can assist in the identification of appropriate and eligible at-risk patients. Interventional cardiologists are likely to encounter diverse patients with hyperlipidemia who require an adjustment in therapy, and can benefit from education.
Upon completion of this activity, participants will be able to:
-Outline treatment guidelines and recommendations for appropriate patient assessment, treatment selection, and risk stratification strategies within hyperlipidemia
-Interpret outcomes data from studies with the PCSK9 inhibitors
-Discuss the risk assessment of ACS patients with diabetes and implications for PCSK9 outcome data on treatment pathways for these patients
-Explain the rationale for consideration of novel treatment strategies in patients who have not achieved recommended LDL-C levels with standard therapies
-Outline treatment guidelines and recommendations for appropriate patient assessment, treatment selection, and risk stratification strategies within hyperlipidemia
-Interpret outcomes data from studies with the PCSK9 inhibitors
-Discuss the risk assessment of ACS patients with diabetes and implications for PCSK9 outcome data on treatment pathways for these patients
-Explain the rationale for consideration of novel treatment strategies in patients who have not achieved recommended LDL-C levels with standard therapies
Sponsored by the Academy for Continued Healthcare Learning and Interventional Academy.
Supported by an educational grant from Sanofi-Regeneron Alliance.
Peter Libby, MD (Chair)
Mallinckrodt Professor of Medicine
Harvard Medical School
Cardiovascular Specialist, Brigham
and Women’s Hospital
Boston, Massachusetts
Mallinckrodt Professor of Medicine
Harvard Medical School
Cardiovascular Specialist, Brigham
and Women’s Hospital
Boston, Massachusetts
Raj Dave, MD, FACC, FSCAI (Co-chair)
Chief Medical Executive
Holy Spirit Cardiovascular Institute
Chairman, Department of Cardiology
Director, Cardiac Catheterization Laboratories
The Ortenzio Heart Center at Holy Spirit Hospital
Camp Hill, Pennsylvania
Alan Brown, MD
Director, Division of Cardiology
Advocate Heart Institute at Lutheran General Hospital
President, National Lipid Society
President, National Lipid Society
Park Ridge, Illinois
Nihar Desai, MD, MPH
Assistant Professor of Medicine
Yale School of Medicine
West Haven, Connecticut
Dinesh Kalra, MD, FACC
Assistant Professor
Rush University Medical Center
Chicago, Illinois
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in a CME/CE activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been resolved prior to this CME activity. The following financial relationships have been provided:
Raj Dave, MD, FACC, FSCAI
-Board Member/Advisory Panel/Speakers Bureau: Abbott Vascular, Amgen, Aralez, Astellas, Boston Scientific Corporation, Bristol-Myers Squibb, Chiesi USA Inc, Pfizer, QT Vascular, Regeneron, Sanofi-Aventis
-Sources of Funding for Research: Abbott Vascular
-Discussion of Off-Label, Investigational, or Experimental Drug Use: None
Peter Libby, MD
-Board Member/Advisory Panel: Amgen, Athera biotechnologies, Corvidia Therapeutics, DalCor Pharmaceuticals, Kowa Pharmaceuticals, Medimmune
-Consulting Agreements: AstraZeneca, Esperion Therapeutics, Ionis Pharmaceuticals, Sanofi Regeneron, Takeda Pharmaceuticals, XBioTech
-Sources of Funding for Research: Novartis
-Discussion of Off-Label, Investigational, or Experimental Drug Use: None
Alan Brown, MD
-Board Member/Advisory Panel/Speakers Bureau: Akcea, Amgen, Kowa, Regeneron, Sanofi
-Discussion of Off-Label, Investigational, or Experimental Drug Use: None
Nihar Desai, MD, MPH
-No relevant financial relationship to disclose
-Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: None
Dinesh Kalra, MD, FACC
-No relevant financial relationship to disclose
-Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: None
ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.
Recommendations involving clinical medicine in a continuing medical education CME activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
This activity will take approximately 75 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity and complete the posttest and evaluation. To receive credit, 80% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Academy for Continued Healthcare Learning (ACHL) and Interventional Academy. ACHL is accredited by the ACCME to provide continuing medical education for physicians.
ACHL designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.